IMULDOSA ACCESS GUIDE

Start with the exact product, route and treatment phase.

Imuldosa (ustekinumab-srlf) is Accord BioPharma’s FDA-approved biosimilar to Stelara (ustekinumab). FDA describes a biosimilar as highly similar to its reference product with no clinically meaningful differences. Imuldosa was first approved in October 2024; in June 2026, FDA approved its two subcutaneous prefilled syringes and intravenous vial as interchangeable with the matching U.S.-Stelara presentations. [1] [2] [3]

What that does not decide: FDA biosimilar or interchangeable status does not tell you whether a particular plan prefers Imuldosa, whether an authorization is complete, or whether a claim will be paid. CMS likewise says that having an HCPCS Level II code does not by itself determine coverage or payment. [5]

IV and subcutaneous Imuldosa are not the same access event

Intravenous (IV) Infusion presentation

The FDA label lists a 130 mg/26 mL single-dose vial for IV infusion. For adults with Crohn’s disease or ulcerative colitis, the labeled induction phase is one weight-based IV infusion prepared and administered by a healthcare professional.

Subcutaneous (SC) Prefilled syringes

The FDA label lists 45 mg/0.5 mL and 90 mg/mL single-dose prefilled syringes. For adults with Crohn’s disease or ulcerative colitis, labeled maintenance is 90 mg SC eight weeks after the IV induction dose and every eight weeks after that. The labeled route for plaque psoriasis and psoriatic arthritis is SC.

These are label facts for access navigation, not treatment instructions. The prescribing clinician determines the appropriate product, regimen and route. [1]

Why the phase change matters for coverage work
Authorization
Ask whether the approval covers the exact Imuldosa presentation and route, and—when applicable—both IV induction and SC maintenance. Do not assume one approval automatically covers the other phase.
Benefit
Ask the plan which benefit and fulfillment path handles each phase. The FDA label defines route and dosing; it does not assign a medical or pharmacy benefit.
Claim
Ask the treatment site or pharmacy to compare the product, route, site, date range and billing details with the authorization before resubmitting a rejected claim.

Current HCPCS code: Q5098

CMS contractor guidance lists Q5098 as “Injection, ustekinumab-srlf (Imuldosa), biosimilar, 1 mg,” effective July 1, 2025. In that article, Q5098 is marked as a drug with more than one route: JA identifies IV administration and JB identifies subcutaneous administration. [4]

Use the code as a checkpoint, not a coverage answer. The JA/JB instruction above comes from the cited Medicare contractor article. A different payer or billing setting may have different instructions. Ask the billing team which code, units, modifier and product identifier the responsible payer requires. CMS states that an HCPCS code identifies an item or service but does not itself establish coverage or payment. [5]

Product preference is a separate question

An answer such as “ustekinumab is covered” may still leave the exact product unresolved. Ask for the plan’s current preferred ustekinumab product for the diagnosis, route and treatment phase involved. If the plan prefers another reference product or biosimilar, ask for the written preference rule and whether there is an exception process. Then have the prescriber and authorization team confirm that any request names the intended product. This page does not recommend switching products.

AccordCares and manufacturer support

Accord BioPharma says AccordCares can support copay benefits investigation, prior authorization, billing and coding information, and identification of alternate coverage. The official Imuldosa site also provides a patient financial-support page and a prescription/enrollment form for the care team. [6] [7] [8]

Keep assistance and insurance decisions separate. Manufacturer support does not guarantee insurer approval or payment. Eligibility, benefits and program terms can change; verify the current official terms before sharing information or relying on assistance.
Questions to ask when access or a claim is stuck
  • Denied: What is the exact denial reason, the written policy or formulary rule used, its effective date, and the appeal or exception deadline?
  • Incorrect or incomplete authorization: Does the approval name Imuldosa or ustekinumab-srlf and match the route, treatment phase, dose, site, provider and date range that will actually be used?
  • Crohn’s disease or ulcerative colitis: Were IV induction and SC maintenance reviewed as separate access steps, and does the maintenance approval begin when the labeled phase changes?
  • Product preference: Which exact ustekinumab product is preferred for this situation, and can the prescriber request an exception if clinically appropriate?
  • Claim problem: Do the claim’s product identifier, Q5098 units, route modifier when required, administration site and date match both the service delivered and the authorization?
  • Next owner: Is the correction the responsibility of the insurer, prescriber, infusion center, specialty pharmacy or billing office—and who will confirm completion?

Ask for the answer in writing when possible, keep the denial or explanation of benefits, and record the call reference number. A clerical claim correction, a new authorization request, a formulary exception and an appeal are different paths; the written reason tells the care team which path to use.

Official sources

  1. FDA: Imuldosa Prescribing Information, revised June 2026
  2. FDA: June 5, 2026 interchangeability supplement approval letter
  3. FDA Purple Book: Imuldosa product details and reference product
  4. CMS Medicare Coverage Database: Article A53032, Q5098 and JA/JB route modifiers
  5. CMS: HCPCS Level II coding procedures and coverage limitation
  6. Accord BioPharma: AccordCares support services
  7. Imuldosa: official patient financial-support page
  8. AccordCares: Imuldosa prescription and enrollment form

Sources reviewedOctober 6, 2026. Recheck official sources because labels, coding instructions, payer rules and support terms can change.